Two major Lp(a) risk variants (rs10455872 and rs3798220) associated with elevated Lp(a) and increased risk of coronary artery disease have been linked with plaque rupture, though not with plaque erosion.
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.